Nanexa and Applied Materials, Inc. have collaborated since 2020 regarding production equipment to be used for upscaling of the PharmaShell process. The companies have now agreed to terminate the collaboration.
Through the settlement, which enters into force immediately, Nanexa receives a one-time payment of USD 750,000. Applied Materials' exclusive right to supply manufacturing equipment to Nanexa ends, as will the companies' mutual right to use each other's intellectual property rights as well as take part of future revenues.
"We have appreciated the collaboration with Applied Materials but so far, the need for large scale equipment has been very limited, but we expect a change in that respect during the coming years. The market for this type of manufacturing equipment has developed since the collaboration agreement with Applied Materials was signed. Therefore, we see this point in time as suitable to terminate the exclusive agreement with Applied Materials to instead connect with one or more partners that already have large scale manufacturing equipment on the market. I am now looking forward to having the possibility to initiate such discussions" says David Westberg, CEO Nanexa.
For additional information, please contact:
David Westberg - CEO, Nanexa AB (publ)
Phone: +46 70 942 83 03
Email: david.westberg@nanexa.se
www.nanexa.com
The company's Certified Adviser is Carnegie Investment Bank AB (publ).
About Nanexa AB (publ)
Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® - the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others Novo Nordisk and AstraZeneca.
Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).
This information is information that Nanexa is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-05-05 21:35 CEST.
